Comparative Pharmacology
Head-to-head clinical analysis: DIVALPROEX SODIUM versus EQUETRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIVALPROEX SODIUM versus EQUETRO.
DIVALPROEX SODIUM vs EQUETRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases brain concentrations of gamma-aminobutyric acid (GABA), blocks voltage-gated sodium channels, and modulates T-type calcium channels.
Equetro (carbamazepine extended-release) is an anticonvulsant and mood stabilizer. It stabilizes the inactivated state of voltage-gated sodium channels, thereby inhibiting repetitive neuronal firing and reducing synaptic transmission. It also potentiates GABA receptors and inhibits glutamate release.
10-15 mg/kg/day orally in divided doses; increase by 5-10 mg/kg/week; maximum 60 mg/kg/day. Extended-release: 25 mg/kg/day orally; increase by 15 mg/kg/day at weekly intervals; maximum 60 mg/kg/day.
Initial: 50 mg orally twice daily; increase by 50-100 mg/day every 2-4 weeks. Usual maintenance: 100-200 mg orally twice daily. Maximum: 200 mg orally twice daily.
None Documented
None Documented
9-16 hours (terminal); shorter in children (6-9 hours) and longer in hepatic disease or elderly; clinical context: twice-daily dosing provides stable trough concentrations.
Carbamazepine: 25-65 hours (initial single dose), 12-17 hours (chronic dosing due to autoinduction); carbamazepine-10,11-epoxide: 5-8 hours.
Renal: <3% unchanged; primarily hepatic metabolism (glucuronidation, beta-oxidation, cytochrome P450), metabolites eliminated renally; fecal: negligible.
Renal: 2% excreted unchanged (carbamazepine) in urine; 15% as carbamazepine-10,11-epoxide; 30% as other metabolites; biliary/fecal: 50-60% as metabolites.
Category D/X
Category C
Anticonvulsant
Anticonvulsant